These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 20232018)
21. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review. Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238 [TBL] [Abstract][Full Text] [Related]
23. Anti-inflammatory activity of tetracyclines. Webster G; Del Rosso JQ Dermatol Clin; 2007 Apr; 25(2):133-5, v. PubMed ID: 17430750 [TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Bench TJ; Jeremias A; Brown DL Pharmacol Res; 2011 Dec; 64(6):561-6. PubMed ID: 21624471 [TBL] [Abstract][Full Text] [Related]
25. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936 [TBL] [Abstract][Full Text] [Related]
26. Tetracyclines: what a rheumatologist needs to know? Attar SM Int J Rheum Dis; 2009 Jul; 12(2):84-9. PubMed ID: 20374324 [TBL] [Abstract][Full Text] [Related]
27. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Golub LM; Ramamurthy NS; McNamara TF; Greenwald RA; Rifkin BR Crit Rev Oral Biol Med; 1991; 2(3):297-321. PubMed ID: 1654139 [TBL] [Abstract][Full Text] [Related]
28. Use of macrolides and tetracyclines for chronic inflammatory diseases. Voils SA; Evans ME; Lane MT; Schosser RH; Rapp RP Ann Pharmacother; 2005 Jan; 39(1):86-94. PubMed ID: 15562139 [TBL] [Abstract][Full Text] [Related]
29. Metalloproteinases and their inhibitors in neurological disease. Lopez-Navarro ER; Gutierrez J Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):27-38. PubMed ID: 34851449 [TBL] [Abstract][Full Text] [Related]
30. Host modulation with tetracyclines and their chemically modified analogues. Golub LM; Suomalainen K; Sorsa T Curr Opin Dent; 1992 Mar; 2():80-90. PubMed ID: 1325849 [TBL] [Abstract][Full Text] [Related]
31. Role of matrix metalloproteinases in the inflammatory response in human airway cell-based assays and in rodent models of airway disease. Birrell MA; Wong S; Dekkak A; De Alba J; Haj-Yahia S; Belvisi MG J Pharmacol Exp Ther; 2006 Aug; 318(2):741-50. PubMed ID: 16690722 [TBL] [Abstract][Full Text] [Related]
33. Biological activity and clinical implications of the matrix metalloproteinases. Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085 [TBL] [Abstract][Full Text] [Related]
34. Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis. Seftor EA; Seftor RE; Nieva DR; Hendrix MJ Adv Dent Res; 1998 Nov; 12(2):103-10. PubMed ID: 9972131 [No Abstract] [Full Text] [Related]
35. The Emerging Role of Epigenetic Mechanisms in the Causation of Aberrant MMP Activity during Human Pathologies and the Use of Medicinal Drugs. Sarker H; Haimour A; Toor R; Fernandez-Patron C Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33920915 [TBL] [Abstract][Full Text] [Related]
36. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Griffin MO; Fricovsky E; Ceballos G; Villarreal F Am J Physiol Cell Physiol; 2010 Sep; 299(3):C539-48. PubMed ID: 20592239 [TBL] [Abstract][Full Text] [Related]
37. [Clinical experience with Ibuprofen. Apropos of 50 cases]. Warembourg H; Ketelers JY Lille Med; 1972 Oct; 17(9):Suppl 6:1308-1. PubMed ID: 4540401 [No Abstract] [Full Text] [Related]